BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

13124 related articles for article (PubMed ID: 11054027)

  • 1. Comparison of two prognostic markers for malignant melanoma: MIA and S100 beta.
    Juergensen A; Holzapfel U; Hein R; Stolz W; Buettner R; Bosserhoff A
    Tumour Biol; 2001; 22(1):54-8. PubMed ID: 11054027
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of S100 protein and MIA protein as serum marker for malignant melanoma.
    Djukanovic D; Hofmann U; Sucker A; Rittgen W; Schadendorf D
    Anticancer Res; 2000; 20(3B):2203-7. PubMed ID: 10928178
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical value of protein S100 and melanoma-inhibitory activity (MIA) in malignant melanoma.
    Tas F; Yasasever V; Duranyildiz D; Camlica H; Ustuner Z; Aydiner A; Topuz E
    Am J Clin Oncol; 2004 Jun; 27(3):225-8. PubMed ID: 15170138
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the Serum Tumor Markers S100 and Melanoma-inhibitory Activity (MIA) in the Monitoring of Patients with Metastatic Melanoma Receiving Vaccination Immunotherapy with Dendritic Cells.
    Uslu U; Schliep S; Schliep K; Erdmann M; Koch HU; Parsch H; Rosenheinrich S; Anzengruber D; Bosserhoff AK; Schuler G; Schuler-Thurner B
    Anticancer Res; 2017 Sep; 37(9):5033-5037. PubMed ID: 28870930
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Melanoma-inhibiting activity, a novel serum marker for progression of malignant melanoma.
    Bosserhoff AK; Kaufmann M; Kaluza B; Bartke I; Zirngibl H; Hein R; Stolz W; Buettner R
    Cancer Res; 1997 Aug; 57(15):3149-53. PubMed ID: 9242442
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Protein S100 beta and Melanoma Inhibitory Activity (MIA): a prospective study of their clinical value for the early detection of metastasis in malignant melanoma].
    Loppin M; Quillien V; Adamski H; Ollivier I; Garlantézec R; Chevrant-Breton J
    Ann Dermatol Venereol; 2007; 134(6-7):535-40. PubMed ID: 17657179
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relevance of MIA and S100 serum tumor markers to monitor BRAF inhibitor therapy in metastatic melanoma patients.
    Sanmamed MF; Fernández-Landázuri S; Rodríguez C; Lozano MD; Echeveste JI; Pérez Gracia JL; Alegre E; Carranza O; Zubiri L; Martín-Algarra S; González A
    Clin Chim Acta; 2014 Feb; 429():168-74. PubMed ID: 24333389
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical use of p-proteasome in discriminating metastatic melanoma patients: comparative study with LDH, MIA and S100B protein.
    Henry L; Fabre C; Guiraud I; Bastide S; Fabbro-Peray P; Martinez J; Lavabre-Bertrand T; Meunier L; Stoebner PE
    Int J Cancer; 2013 Jul; 133(1):142-8. PubMed ID: 23238767
    [TBL] [Abstract][Full Text] [Related]  

  • 9. S100-Beta, melanoma-inhibiting activity, and lactate dehydrogenase discriminate progressive from nonprogressive American Joint Committee on Cancer stage IV melanoma.
    Deichmann M; Benner A; Bock M; Jäckel A; Uhl K; Waldmann V; Näher H
    J Clin Oncol; 1999 Jun; 17(6):1891-6. PubMed ID: 10561230
    [TBL] [Abstract][Full Text] [Related]  

  • 10. S-100B protein and melanoma inhibitory activity protein in uveal melanoma screening. A comparison with liver function tests.
    Missotten GS; Korse CM; van Dehn C; Linders TC; Keunen JE; Jager MJ; Bonfrer JM
    Tumour Biol; 2007; 28(2):63-9. PubMed ID: 17264538
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Serum markers for melanoma].
    Ugurel S
    Hautarzt; 2005 Feb; 56(2):173-84; 185-6. PubMed ID: 15657726
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MIA, a novel serum marker for progression of malignant melanoma.
    Bosserhoff AK; Lederer M; Kaufmann M; Hein R; Stolz W; Apfel R; Bogdahn U; Buettner R
    Anticancer Res; 1999; 19(4A):2691-3. PubMed ID: 10470221
    [TBL] [Abstract][Full Text] [Related]  

  • 13. S100 protein serum levels in cutaneous malignant melanoma.
    Seregni E; Massaron S; Martinetti A; Illeni MT; Rovini D; Belli F; Agresti R; Greco M; Cascinelli N; Bombardieri E
    Oncol Rep; 1998; 5(3):601-4. PubMed ID: 9538159
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rising levels of serum S100 protein precede other evidence of disease progression in patients with malignant melanoma.
    Jury CS; McAllister EJ; MacKie RM
    Br J Dermatol; 2000 Aug; 143(2):269-74. PubMed ID: 10951132
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Melanoma inhibitory activity (MIA), a serological marker of malignant melanoma.
    Bosserhoff AK; Dreau D; Hein R; Landthaler M; Holder WD; Buettner R
    Recent Results Cancer Res; 2001; 158():158-68. PubMed ID: 11092043
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of multiple serum markers in advanced melanoma.
    Díaz-Lagares A; Alegre E; Arroyo A; González-Cao M; Zudaire ME; Viteri S; Martín-Algarra S; González A
    Tumour Biol; 2011 Dec; 32(6):1155-61. PubMed ID: 21858537
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical significance of serum S100 in metastatic malignant melanoma.
    Guo HB; Stoffel-Wagner B; Bierwirth T; Mezger J; Klingmüller D
    Eur J Cancer; 1995 Oct; 31A(11):1898-902. PubMed ID: 8541129
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Results of the determination of serum markers in patients with malignant melanoma.
    Lugović L; Situm M; Buljan M; Poduje S; Sebetić K
    Coll Antropol; 2007 Jan; 31 Suppl 1():7-11. PubMed ID: 17469741
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum S100--a marker for disease monitoring in metastatic melanoma.
    Henze G; Dummer R; Joller-Jemelka HI; Böni R; Burg G
    Dermatology; 1997; 194(3):208-12. PubMed ID: 9187834
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Melanoma progression and serum L-dopa/L-tyrosine ratio: a comparison with S100B.
    Stoitchkov K; Letellier S; Garnier JP; Bousquet B; Tsankov N; Morel P; Ghanem G; Le Bricon T
    Melanoma Res; 2002 Jun; 12(3):255-62. PubMed ID: 12140382
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 657.